Epinephrine maculopathy.
Epinephrine maculopathy is a reversible macular change that occurs in aphakic eyes being treated with topical epinephrine compounds. The first symptom is transient blurred vision, which can be followed by decreased visual acuity, flame-shaped hemorrhages, and cystoid macular edema. Onset of symptoms can range from a few days after the commencement of epinephrine therapy to several months thereafter. Epinephrine maculopathy should be differentiated from Irvine-Gass syndrome. Treatment consists of changing the patient's therapeutic regimen for glaucoma to other pharmaceutical agents. When this is done recovery of pre-maculopathy visual acuity and reversal of cystic macular changes usually occur.
D001036:Aphakia, Postcataract / Q000150:complications*; D003560:Cysts / Q000139:chemically induced; D004487:Edema / Q000139:chemically induced; D004837:Epinephrine / Q000009:adverse effects*; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D008266:Macula Lutea; D012075:Remission, Spontaneous; D012164:Retinal Diseases / Q000139:chemically induced; D012166:Retinal Hemorrhage / Q000139:chemically induced
D004837:Epinephrine